TY - JOUR
T1 - A global system for the next generation of vaccines
AU - Arinaminpathy, Nimalan
AU - Saad-Roy, Chadi M.
AU - Yang, Qiqi
AU - Ahmad, Isa
AU - Yadav, Prashant
AU - Grenfell, Bryan
N1 - Funding Information:
Theauthors thankS.SuvanandandD.Lewinsohn forhelpful commentson futureTBvaccines.In addition to thefunding forthis workfromFluLab,C.M.S.-R.acknowledgessupport from a Postgraduate Doctoral Scholarship of the Natural Sciences and Engineering Research Council of Canada and from a Charlotte Elizabeth Procter Fellowship of Princeton University.N.A.acknowledges supportfromtheMRCCentre forGlobal InfectiousDiseaseAnalysis(referenceMR/ R015600/1).
Funding Information:
The authors thank S. Suvanand and D. Lewinsohn for helpful comments on future TB vaccines. In addition to the funding for this work from FluLab, C.M.S.-R. acknowledges support from a Postgraduate Doctoral Scholarship of the Natural Sciences and Engineering Research Council of Canada and from a Charlotte Elizabeth Procter Fellowship of Princeton University. N.A. acknowledges support from the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1).
Publisher Copyright:
Copyright © 2022 The Authors
PY - 2022/4/29
Y1 - 2022/4/29
N2 - The rapid development of vaccines against COVID-19 raises questions about what could be achieved in vaccines to other major diseases. Influenza presents an important case study; it is one of the few infections that causes substantial public health burden in its endemic form while also having proven pandemic potential. We offer a first step in bringing together the value proposition of future influenza vaccines considering two key characteristics: the breadth of protection that vaccines offer (against individual strains, all strains within a subtype, multiple subtypes, or all subtypes) and the duration for which protection remains effective (see the figure). We examine implications of these characteristics, from both epidemiologic and economic perspectives, and discuss how a future market for influenza vaccines might best align public health and economic incentives. Although many of these factors are specific to influenza, we consider comparisons with other major infections, such as tuberculosis and COVID-19.
AB - The rapid development of vaccines against COVID-19 raises questions about what could be achieved in vaccines to other major diseases. Influenza presents an important case study; it is one of the few infections that causes substantial public health burden in its endemic form while also having proven pandemic potential. We offer a first step in bringing together the value proposition of future influenza vaccines considering two key characteristics: the breadth of protection that vaccines offer (against individual strains, all strains within a subtype, multiple subtypes, or all subtypes) and the duration for which protection remains effective (see the figure). We examine implications of these characteristics, from both epidemiologic and economic perspectives, and discuss how a future market for influenza vaccines might best align public health and economic incentives. Although many of these factors are specific to influenza, we consider comparisons with other major infections, such as tuberculosis and COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85129387654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129387654&partnerID=8YFLogxK
U2 - 10.1126/science.abm8894
DO - 10.1126/science.abm8894
M3 - Article
C2 - 35482858
AN - SCOPUS:85129387654
SN - 0036-8075
VL - 376
SP - 462
EP - 464
JO - Science
JF - Science
IS - 6592
ER -